Literature DB >> 34272705

Sources of Interindividual Variability.

Yvonne S Lin1, Kenneth E Thummel2, Brice D Thompson2, Rheem A Totah3, Christi W Cho3.   

Abstract

The efficacy, safety, and tolerability of drugs are dependent on numerous factors that influence their disposition. A dose that is efficacious and safe for one individual may result in sub-therapeutic or toxic blood concentrations in others. A significant source of this variability in drug response is drug metabolism, where differences in presystemic and systemic biotransformation efficiency result in variable degrees of systemic exposure (e.g., AUC, Cmax, and/or Cmin) following administration of a fixed dose.Interindividual differences in drug biotransformation have been studied extensively. It is recognized that both intrinsic factors (e.g., genetics, age, sex, and disease states) and extrinsic factors (e.g., diet , chemical exposures from the environment, and the microbiome) play a significant role. For drug-metabolizing enzymes, genetic variation can result in the complete absence or enhanced expression of a functional enzyme. In addition, upregulation and downregulation of gene expression, in response to an altered cellular environment, can achieve the same range of metabolic function (phenotype), but often in a less predictable and time-dependent manner. Understanding the mechanistic basis for variability in drug disposition and response is essential if we are to move beyond the era of empirical, trial-and-error dose selection and into an age of personalized medicine that will improve outcomes in maintaining health and treating disease.
© 2021. Springer Science+Business Media, LLC, part of Springer Nature.

Keywords:  Disease; Gender; Interindividual variability; Pharmacogenomics; Pregnancy

Year:  2021        PMID: 34272705     DOI: 10.1007/978-1-0716-1554-6_17

Source DB:  PubMed          Journal:  Methods Mol Biol        ISSN: 1064-3745


  475 in total

Review 1.  Pharmacogenetics of the major polymorphic metabolizing enzymes.

Authors:  A K Daly
Journal:  Fundam Clin Pharmacol       Date:  2003-02       Impact factor: 2.748

Review 2.  Definition and clinical importance of haplotypes.

Authors:  Dana C Crawford; Deborah A Nickerson
Journal:  Annu Rev Med       Date:  2005       Impact factor: 13.739

Review 3.  From human genetics and genomics to pharmacogenetics and pharmacogenomics: past lessons, future directions.

Authors:  Daniel W Nebert; Ge Zhang; Elliot S Vesell
Journal:  Drug Metab Rev       Date:  2008       Impact factor: 4.518

Review 4.  Pharmacogenomics of drug-metabolizing enzymes: a recent update on clinical implications and endogenous effects.

Authors:  S C Sim; M Kacevska; M Ingelman-Sundberg
Journal:  Pharmacogenomics J       Date:  2012-10-23       Impact factor: 3.550

5.  Mechanisms of Cytochrome P450-Catalyzed Oxidations.

Authors:  F Peter Guengerich
Journal:  ACS Catal       Date:  2018-10-18       Impact factor: 13.084

6.  Deletion of the entire cytochrome P450 CYP2D6 gene as a cause of impaired drug metabolism in poor metabolizers of the debrisoquine/sparteine polymorphism.

Authors:  A Gaedigk; M Blum; R Gaedigk; M Eichelbaum; U A Meyer
Journal:  Am J Hum Genet       Date:  1991-05       Impact factor: 11.025

Review 7.  Cytochrome P450 enzymes in drug metabolism: regulation of gene expression, enzyme activities, and impact of genetic variation.

Authors:  Ulrich M Zanger; Matthias Schwab
Journal:  Pharmacol Ther       Date:  2013-01-16       Impact factor: 12.310

8.  Physiological Content and Intrinsic Activities of 10 Cytochrome P450 Isoforms in Human Normal Liver Microsomes.

Authors:  Hai-Feng Zhang; Huan-Huan Wang; Na Gao; Jun-Ying Wei; Xin Tian; Yan Zhao; Yan Fang; Jun Zhou; Qiang Wen; Jie Gao; Yang-Jun Zhang; Xiao-Hong Qian; Hai-Ling Qiao
Journal:  J Pharmacol Exp Ther       Date:  2016-05-09       Impact factor: 4.030

Review 9.  Pharmacogenomics.

Authors:  Dan M Roden; Howard L McLeod; Mary V Relling; Marc S Williams; George A Mensah; Josh F Peterson; Sara L Van Driest
Journal:  Lancet       Date:  2019-08-05       Impact factor: 79.321

Review 10.  Pharmacogenetics: a general review on progress to date.

Authors:  Ann K Daly
Journal:  Br Med Bull       Date:  2017-12-01       Impact factor: 4.291

View more
  1 in total

Review 1.  Isoquercetin as an Anti-Covid-19 Medication: A Potential to Realize.

Authors:  Majambu Mbikay; Michel Chrétien
Journal:  Front Pharmacol       Date:  2022-03-02       Impact factor: 5.810

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.